Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC predicts end-market recovery for Volution, ups target price

(Sharecast News) - RBC Capital Markets has raised its target price for Volution Group from 700p to 740p after the ventilation products maker's better-than-expected second-half performance, keeping an 'outperform' rating on the stock. The broker said that results for the year to 31 July should come in ahead of forecasts, with the company pointing to revenue growth of "over 20%" at constant currency, compared with RBC's 18.6% improvement expected, due to a strong performance in the UK and the integration of Fantech, acquired in December.

The guidance "underscores our positive outlook" for the next financial year, RBC said, predicting a recovery in underlying construction markets.

"There are evidently some signs of improvement in new build already, though we expect the more fulsome recovery across underlying markets has been pushed further into 2026," the broker said.

"Meanwhile, we expect FAN to continue its solid performance with a focused organic growth strategy, augmented by efficiency improvements in support of margins, and a well-oiled M&A strategy."

The stock, which jumped 4% on Thursday following the update, was up a further 0.7% at 661.3p by 1006 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.